Sarpogrelate- another new antiplatelet agent?
Shaikh, Q.; Kamal, A.K.
JPMA. Journal of the Pakistan Medical Association 62(11): 1253
2012
ISSN/ISBN: 0030-9982 PMID: 23866425 Document Number: 656265
Document emailed within 1 workday
Related Documents
Hasegawa, T.; Hasegawa, S.; Fukushima, K.; Take, A.; Horimi, H. 1986: Superior vena cava reconstruction with an antiplatelet agent Nihon Kyobu Geka Gakkai 34(6): 857-861Hara, H.; Osakabe, M.; Kitajima, A.; Tamao, Y.; Kikumoto, R. 1991: MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist Thrombosis and Haemostasis 65(4): 415-420
Hinneburg, I. 2011: Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome Medizinische Monatsschrift für Pharmazeuten 34(7): 226-232
Han, B.H.; Suh, D.Y.; Yang, H.O.; Park, Y.H.; Kang, Y.H.; Kim, Y.C. 1994: Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity Arzneimittel-Forschung 44(10): 1122-1126
Komuro, M.; Hori, W.; Hotta, M.; Saitoh, S.; Ishida, R.; Uchida, H. 1992: Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in laboratory animals Arzneimittel-Forschung 42(1): 55-59
Momo, K.; Someya, K.; Tachiiri, T.; Mitsuoka, Y.; Nakamura, K.; Imai, S.; Ino, T.; Ohkubo, H. 1992: Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals Arzneimittel-Forschung 42(1): 32-39
Khan, M.; Kamal, A.Kamran. 2010: What is the best antiplatelet agent for prevention of recurrent stroke in Pakistani patients? Do combinations offer significant advantages in the South Asian context? Jpma. Journal of the Pakistan Medical Association 60(9): 783-784
Kumagai, S.; Morinobu, A.; Ozaki, S.; Nakao, K.; Ishida, H. 1998: Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases Ryumachi 38(3): 504-510
Hollán, Z. 1986: Is the HTLV III/LAV virus the causative agent of AIDS or merely an agent of one of the opportunistic infections? Orvosi Hetilap 127(52): 3219-3220
Rider, J.A. 1976: Small bowel motility: comparison of the effects of an anticholinergic agent, this agent plus a tranquilizer, and a placebo Current Therapeutic Research 20(2): 142-148
Ziebolz, D.; Hannig, C.; Attin, T. 2008: Influence of a desensitizing agent on efficacy of a paint-on bleaching agent American Journal of Dentistry 21(2): 77-82
Short, C.E.; Miller, R.L. 1978: Comparative evaluation of the anticholinergic agent glycopyrrolate as a preanesthetic agent Veterinary Medicine-Small Animal Clinician 73(10): 1269-1273
Naess, K. 1973: A beta blocking agent as an antihypertensive agent Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 93(27): 2041
El-Fiky, S.M.; Fahmy, T.Y.; Ameen, A.M. 1971: Morpho-topochemical studies of Golgi apparatus and Vitamin C in normal mammary gland cells of agent free C3Hf and agent carrying the MTV in C3H mouse strain Acta Histochemica 41(1): 131-136
Gomes, O.M. 1982: Antiplatelet agents: how much? which one? for whom? Arquivos Brasileiros de Cardiologia 38(1): 1-2
Wynn, R.L. 2012: New antiplatelet and anticoagulant drugs General Dentistry 60(1): 8-11
Ishikawa, K. 2003: Anticoagulant, antiplatelet agents Nihon Rinsho. Japanese Journal of Clinical Medicine 61(Suppl 4): 647-653
De Caterina, R.; Blanco, A. 1992: Nitrates as antiplatelet agents Sangre 37(1): 31-38
Coccheri, S. 2013: New antiplatelet agents: are we better off now than we were with aspirin? Clinical Advances in Hematology and Oncology: H&o 11(12): 787-790
Bounameaux, H. 1994: Trials of antiplatelet therapy Bmj 308(6940): 1371-1372